Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
BUSINESS
Takeda Joins Fight against COVID-19, Eyes Plasma Product Launch in 9-18 Months
Takeda Pharmaceutical will develop an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) for the treatment of high-risk patients with the novel coronavirus disease COVID-19, looking to roll it out within nine months at the earliest. The development plan for H-IG, coded TAK-888,…
To read the full story
Related Article
- Takeda/CSL-Led Alliance’s COVID-19 Plasma Therapy Fails in PIII
April 5, 2021
- Takeda-Led Alliance Kicks Off Global PIII for COVID-19 Plasma Therapy
October 12, 2020
- Takeda, US Arrowhead Join Forces on Intractable Liver Disease Therapy
October 12, 2020
- Takeda Exec Says Plasma Alliance Could Start Clinical Trial for Unbranded Therapy in July
May 14, 2020
- 4 Players Join Plasma Alliance to Develop Unbranded Immunoglobulin for COVID-19, Global Study Slated for This Summer
May 11, 2020
- Takeda, CSL, Other Firms Join Hands to Develop Unbranded Immunoglobulin for COVID-19
April 7, 2020
BUSINESS
- Meiji Pharma Sues CDP Lawmaker for Defamation over Kostaive
December 26, 2024
- ASKA In-Licenses Another Women’s Health Drug from Insud
December 26, 2024
- Sandoz’s Rituximab Biosimilar Adds Pediatric ITP Indication
December 26, 2024
- Nihon Servier Files Glioma Drug Vorasidenib in Japan
December 25, 2024
- Sumitomo’s Gemtesa Expands Label in US to OAB Patients with BPH
December 25, 2024
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…